Small-molecule and peptide inhibitors of m6A regulators

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• N6-methyladenosine (m6A) is a key reversible mRNA modification implicated in malignant tumor progression.
• m6A modification and its regulatory factors are increasingly recognized for their roles in various cancers.
• m6A regulators and modifications show promise as biomarkers for cancer prognosis and treatment.

Purpose of the Study:

• To review the current understanding of m6A regulatory factors in malignant tumors.
• To summarize the development and application of small-molecule and peptide inhibitors targeting m6A regulators for cancer therapy.
• To explore the therapeutic potential and mechanisms of m6A inhibitors in diverse cancers.

Main Methods:

• Literature review of studies on m6A modification in cancer.
• Analysis of research on m6A regulatory factors and their inhibitors.
• Synthesis of information on the efficacy and mechanisms of m6A inhibitors in tumor therapy.

Main Results:

• m6A modifications and regulatory proteins are significant biomarkers for cancer treatment and prognosis.
• Research into m6A regulatory factor inhibitors is rapidly expanding.
• m6A inhibitors show potential for integration with existing cancer therapies.

Conclusions:

• m6A regulators are critical targets for novel cancer therapies.
• Development of specific m6A inhibitors holds promise for advancing pharmaceutical development and clinical applications in oncology.
• Targeting m6A modifications offers a new avenue for effective and selective cancer treatment strategies.